Algernon Pharmaceuticals (AGN) AI Stock Analysis

• Market Cap: $2.23M
• Dividend Yield: N/A
• Average Volume (3M): 25.27K
• Price to Earnings (P/E): 2.8
• Beta (1Y): 0.15
• Revenue Growth: N/A
• EPS Growth: 64.77%
• Country: CA
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 34,256,218
• 10 Day Avg. Volume: 12,821
• 30 Day Avg. Volume: 25,272
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -87.26
• Enterprise Value/Ebitda: -1.29
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: ―

Algernon Pharmaceuticals faces significant financial hurdles with zero revenue generation and ongoing operational losses, contributing to a low overall score. The technical indicators further suggest bearish momentum, while the valuation appears relatively attractive due to a low P/E ratio. However, the lack of earnings call and corporate events data limits further insight into potential future performance.

Algernon Pharmaceuticals Business Overview & Revenue Model

Company Description

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Algernon Pharmaceuticals makes money through the development and commercialization of its pharmaceutical products. The company focuses on repurposing existing drugs, which can streamline the approval process and reduce costs associated with drug development. Revenue is primarily generated through licensing agreements, partnerships with larger pharmaceutical companies, and potential sales of its proprietary compounds once approved. Additionally, Algernon may secure funding through grants or investment in its research and development initiatives. The company's earnings are influenced by the success of its clinical trials, regulatory approvals, and the ability to establish strategic partnerships for commercialization.

Algernon Pharmaceuticals Financial Statement Overview

Summary

Algernon Pharmaceuticals is facing significant financial challenges with zero revenue and operational losses. Although the balance sheet shows no debt and a reliance on equity, cash burn remains a persistent issue. The company needs to focus on generating revenue and improving operational efficiencies.

Income Statement

The company has consistently reported zero revenue, indicating a lack of commercialized products or services. Despite a reported positive net income in the TTM (Trailing-Twelve-Months), historical data shows significant net losses, demonstrating instability. The negative EBIT and EBITDA margins highlight ongoing operational challenges.

Balance Sheet

The company has a strong equity position with zero debt, reflected in a Debt-to-Equity Ratio of zero. However, the shrinking asset base and equity over the years suggest potential financial strain. The Equity Ratio shows moderate reliance on equity financing.

Cash Flow

Operating cash flows have been consistently negative, indicating operational cash challenges. Free cash flow has also been negative, pointing to cash outflows exceeding cash inflows. Financing activities have been necessary to support operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-25.61K	-26.56K	-50.40K	-34.94K	0.00	0.00
EBITDA	-1.73M	-476.42K	-4.98M	-6.02M	-8.05M	-8.54M
Net Income	-1.76M	-502.98K	-6.78M	-6.05M	-7.73M	-8.54M
Balance Sheet
Total Assets	4.88M	3.94M	4.19M	8.14M	10.14M	12.82M
Cash, Cash Equivalents and Short-Term Investments	88.18K	596.20K	125.08K	1.41M	2.41M	6.12M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	3.14M	1.78M	2.72M	2.52M	1.02M	607.05K
Stockholders Equity	1.74M	2.17M	1.47M	5.62M	9.12M	12.22M
Cash Flow
Free Cash Flow	-1.33M	-2.79M	-2.61M	-3.06M	-7.95M	-6.71M
Operating Cash Flow	-1.30M	-2.71M	-2.55M	-2.91M	-7.82M	-6.61M
Investing Cash Flow	155.75K	2.28M	-59.50K	-144.61K	-124.45K	-99.74K
Financing Cash Flow	628.23K	901.09K	1.33M	2.06M	4.25M	12.62M

Algernon Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AGN, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.35 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AGN.

Algernon Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZOMD	79 Outperform	C$208.67M	9.27	59.66%	―	91.28%	623.60%
AGN	43 Neutral	$2.23M	2.79	-93.09%	―	―	64.77%
ONC	43 Neutral	C$144.24M	―	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Algernon Pharmaceuticals Corporate Events

Algernon NeuroScience Partners with Validcare for Pioneering Stroke Study

Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals, has appointed Validcare as the contract research organization for its upcoming Phase 2a DMT stroke trial in Europe. This trial will involve 40 stroke patients and is set to begin in the third quarter of 2025. Validcare, a U.S.-based CRO, has also invested $170,000 in Algernon NeuroScience, aligning incentives for efficient trial execution. The partnership aims to explore DMT’s potential in treating strokes by observing its effectiveness in reducing damage and restoring motor function. Additionally, Algernon Pharmaceuticals has announced the cancellation of 684,000 stock options previously granted to company officials.